{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.5","value":"31.3"},{"groupId":"OG001","spread":"0","value":"25.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"The Musculoskeletal Tumor Rating Scale (MSTS) is a measure of physical function across 7 items, completed by the physician (preferably by the Orthopedic Surgeon or Surgical Oncologist) or the physician's designated staff. The 7 items are: pain, range of motion, strength, joint stability, joint deformity, emotional, acceptance, and overall function. Each item is scored from 0-5 (worst possible to best possible condition). The item scores are summed to get the total score which ranges from 0-35.\n\nLate radiation morbidity is defined as ≥ grade 2 lymphedema, subcutaneous fibrosis, or joint stiffness. Adverse events are graded using CTCAE v3.0. Grade refers to the severity of the AE. The CTCAE v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE.","dispersionType":"Standard Deviation","groups":[{"id":"OG000","title":"No Late Radiation Morbitity"},{"id":"OG001","title":"Has Late Radiation Toxicity"}],"paramType":"MEAN","populationDescription":"All eligible patients on Cohort B who had a 2-year MSTS assessment. (See limitations and caveats, Cohort A is not included.)","reportingStatus":"POSTED","timeFrame":"From start of treatment to 2 years.","title":"Mean Musculoskeletal Tumor Rating Scale (MSTS) by Late Radiation Morbidity at Two Years","type":"SECONDARY","unitOfMeasure":"units on a scale"}